Levetiracetam (Epilepsy) updated on 04-22-2025

Minor congenital malformations

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S16807
R70520
Ertürk Çetin (Epilepsy) (Levetiracetam), 2024 At least one minor anomaly throughout pregnancy prospective cohort exposed to other treatment, sick Adjustment: No 3.33 [0.59;18.89] C 12/18   3/8 15 18
ref
S15842
R65222
Bromley (Levetiracetam) (Controls exposed to LTG), 2023 Minor congenital anomaly during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick excluded Adjustment: No 0.36 [0.07;1.75] C
excluded (control group)
2/70   8/106 10 70
ref
S15843
R65235
Bromley (Levetiracetam) (Controls unexposed, sick), 2023 Minor congenital anomaly during pregnancy (anytime or not specified) excluded prospective cohort unexposed, sick Adjustment: No 2.32 [0.21;26.19] C
excluded (exposition period)
2/70   1/80 3 70
ref
S12502
R47878
Mari (Levetiracetam), 2022 Minor congenital malformations throughout pregnancy retrospective cohort exposed to other treatment, sick Adjustment: No 2.03 [0.08;54.83] C 1/17   0/11 1 17
ref
S16700
R70271
Alsaadi (Controls exposed to LTG), 2020 Minor congenital malformations 1st trimester retrospective cohort exposed to other treatment, sick excluded Adjustment: No 0.09 [0.00;2.46] C
excluded (control group)
0/38   1/12 1 38
ref
S16701
R70275
Alsaadi (Controls unexposed sick), 2020 Minor congenital malformations 1st trimester retrospective cohort unexposed, sick Adjustment: No 0.95 [0.02;49.01] C 0/38   0/36 0 38
ref
Total 3 studies 2.57 [0.62;10.76] 16 73
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Ertürk Çetin (Epilepsy) (Levetiracetam), 2024Ertürk Çetin, 2024 1 3.33[0.59; 18.89]151868%ROB confusion: criticalROB selection: unclearROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Mari (Levetiracetam), 2022Mari, 2022 2 2.03[0.08; 54.83]11719%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: unclear Alsaadi (Controls unexposed sick), 2020Alsaadi, 2020 3 0.95[0.02; 49.01]03813%ROB confusion: criticalROB selection: unclearROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Total (3 studies) I2 = 0% 2.57[0.62; 10.76]16730.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Epilepsy) (Levetiracetam; 2: Levetiracetam; 3: Controls unexposed sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.57[0.62; 10.76]16730%NAErtürk Çetin (Epilepsy) (Levetiracetam), 2024 Mari (Levetiracetam), 2022 Alsaadi (Controls unexposed sick), 2020 3 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.95[0.02; 49.01]-38 -NAAlsaadi (Controls unexposed sick), 2020 1 exposed to other treatment, sickexposed to other treatment, sick 2.99[0.65; 13.90]16350%NAErtürk Çetin (Epilepsy) (Levetiracetam), 2024 Mari (Levetiracetam), 2022 2 Tags Adjustment   - No  - No 2.57[0.62; 10.76]16730%NAErtürk Çetin (Epilepsy) (Levetiracetam), 2024 Mari (Levetiracetam), 2022 Alsaadi (Controls unexposed sick), 2020 3 All studiesAll studies 2.57[0.62; 10.76]16730%NAErtürk Çetin (Epilepsy) (Levetiracetam), 2024 Mari (Levetiracetam), 2022 Alsaadi (Controls unexposed sick), 2020 30.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 16700, 15842

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 0.95[0.02; 49.01]-38 -NAAlsaadi (Controls unexposed sick), 2020 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.16[0.15; 9.26]177344%NAErtürk Çetin (Epilepsy) (Levetiracetam), 2024 Mari (Levetiracetam), 2022 Alsaadi (Controls exposed to LTG), 2020 30.510.01.0